CME Presentations

Dravet Syndrome


Presentations


Speakers

  • Kelly Knupp, MD

    Kelly Knupp, MD

    Kelly Knupp, MD

    Associate Professor of Pediatrics and Neurology

    Kelly Knupp, MD, is associate professor of pediatrics and neurology at the University of Colorado. She practices at Children’s Hospital Colorado in Aurora, where she is associate research director of the Neuroscience Institute, director of the Dravet Program, and co-interim section chief. Dr Knupp’s research interests are epileptic encephalopathies, including Dravet Syndrome. She was a founding member of the Pediatric Epilepsy Research Consortium, which focuses on developing collaborative research nationally for children with epileptic encephalopathies. Dr Knupp serves on the medical advisory boards of the Epilepsy Foundation of Colorado and the Dravet Syndrome Foundation. She received her medical degree from the University of New Mexico School of Medicine in Albuquerque.
  • Elaine C. Wirrell, MD, FRCPC

    Elaine C. Wirrell, MD, FRCPC

    Elaine C. Wirrell, MD, FRCPC

    Consultant and Chief of Pediatric Epilepsy

    Elaine C. Wirrell, MD, FRCPC, is professor of child and adolescent neurology, and consultant and chief of Pediatric Epilepsy at Mayo Clinic in Rochester, Minnesota. Dr Wirrell’s research focuses on epidemiology and the treatment of pediatric epilepsy, as well as comorbidities. Her research has led to 173 peer-reviewed articles and 19 book chapters. Dr Wirrell is chair of the AES Pediatric Content Committee and of the ICNA Research Committee, and co-chair of the ILAE Nosology and Definitions Committee Member: Pediatric Psychiatry Committee. She is a member of the Fellow of the Royal College of Physicians & Surgeons of Canada, the Minnesota Board of Medical Practice, and the American Epilepsy Society. Dr Wirrell received her medical degree from University of British Columbia in Vancouver.
  • Scott Perry, MD

    Scott Perry, MD

    Scott Perry, MD

    Head of Neurosciences

    M. Scott Perry, MD, is the medical director of Neurology and the Genetic Epilepsy Clinic, as well as co-director of the Jane and John Justin Neurosciences Center at Cook Children’s Medical Center in Fort Worth, Texas. His clinical and research interests include the use of epilepsy surgery for the treatment of intractable childhood epilepsy and the evaluation and treatment of genetic epilepsy syndromes. Dr Perry completed his medical degree at the University of Mississippi School of Medicine in Jackson and general pediatrics and child neurology training at Emory University in Atlanta, Georgia. He completed a clinical neurophysiology fellowship at Miami Children’s Hospital before joining Cook Children’s in 2009.
  • Joseph Sullivan, MD

    Joseph Sullivan, MD

    Joseph Sullivan, MD

    Professor of Neurology & Pediatrics

    Joseph Sullivan, MD, is a professor of Neurology and Pediatrics at the University of California, San Francisco (UCSF) and Director of the UCSF Pediatric Epilepsy Center of Excellence at Benioff Children’s Hospital. He has served as principal investigator in clinical trials of novel drugs for rare pediatric epilepsies. Dr. Sullivan is a member of the Dravet Syndrome Foundation Board of Directors and Medical Advisory Board, chair of the PCDH19 Alliance Scientific Advisory board, and past chair of the Pediatric Epilepsy Research Consortium Steering Committee and Epilepsy Foundation of Northern California. He continues to expand UCSF’s Pediatric Epilepsy Center of Excellence to provide family-centric care by hiring specialists that attend to psychosocial needs of patients living with epilepsy.
  • Veronica Hood, PhD

    Veronica Hood, PhD

    Veronica Hood, PhD

    Scientific Director

    Veronica Hood, PhD, is the Scientific Director for the Dravet Syndrome Foundation (DSF). Dr. Hood received her PhD in Cell, Stem Cell, and Developmental Biology from the University of Colorado in 2019. Her previous research focused on cellular and molecular neurobiology related to schizophrenia and disorders of myelination. In addition, Dr. Hood personally understands the caregiver perspective through caring for her son Gabriel, who passed away from an undiagnosed, neurodevelopmental disorder at the age of 8. As the Scientific Director at DSF, Dr. Hood uses her professional training and personal experiences to advance research efforts, advocate for the Dravet community, and facilitate communication and education related to Dravet syndrome amongst professionals and families.
  • Danielle Andrade, MD, MSc, FRCPC, CSCN (EEG)

    Danielle Andrade, MD, MSc, FRCPC, CSCN (EEG)

    Danielle Andrade, MD, MSc, FRCPC, CSCN (EEG)

    Professor of Medicine (Neurology)

    Danielle Andrade, MD, MSc, FRCPC, CSCN (EEG), is a Professor of Medicine (Neurology) at the University of Toronto and the Medical Director of the Epilepsy Program at Toronto Western Hospital. Also, she is the Director of the Adult Epilepsy Genetics Program at University of Toronto and the chair of the ILAE Task Force on Child to Adulthood Transition. Dr. Andrade’s research focus is on genetic epilepsies. As a neurologist treating adult patients with developmental and epileptic encephalopathies (DEEs), she observed that the adult neurologist is not familiar with DEEs, and the natural course of DEEs as patients age, is mostly unknown. Therefore, Dr. Andrade established the adult Epilepsy Genetics Program (A-EGP) to fill a significant gap in the research and care of these patients.
  • Sharon Canino

    Sharon Canino

    Sharon Canino

    Parent of an adult child with Dravet

    Sharon Canino, MS, lives in Southern California with her husband and their daughter, Jessica. Jessica began having severe generalized tonic-clonic seizures at 5-months old and was diagnosed with intractable epilepsy. Jessica's true diagnosis was Dravet Syndrome, and Sharon pivoted her focus toward advocacy for Dravet syndrome. Sharon attended her first Dravet Syndrome Conference in 2012. She has represented the Dravet Syndrome Foundation at the Epilepsy Awareness Expo for the past 9 years, educating families and medical professionals about the work of the DSF and the importance of a correct diagnosis for Dravet patients. ln 2018, Sharon joined the Adult Advisory Committee of DSF and has continued to advocate for the needs of adult Dravet patients and their caregivers.
  • Mary Zupanc, MD

    Mary Zupanc, MD

    Mary Zupanc, MD

    Professor, Department of Pediatrics and Neurology

    Mary Zupanc, MD, is a Clinical Professor of Pediatrics and Neurology at the University of California-Irvine/CHOC-Children’s Hospital. Until June 2021, she was the Co-Medical Director of the CHOC Neuroscience Institute and the University of California-Irvine (UCI) Division Chief for Pediatric Neurology. Dr. Zupanc has been recognized for her scholarship and contributions in the advancement of pediatric neurology, having published many articles in peer reviewed journals in her areas of clinical/translational research: infantile spasms, intractable epilepsy syndromes and appropriate treatments, as well as pediatric epilepsy surgery. At the Child Neurology Society meeting in 2021, Dr. Zupanc was awarded the Arnold P. Gold Foundation Humanism in Medicine Award.

CME Information

Global Logo PQH Logo

Enhancing Dravet Syndrome Outcomes: Strategies for Early Diagnosis and Comprehensive Management

This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the Dravet Syndrome Foundation and the National Organization for Rare Disorders, Inc.

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Zogenix, Inc.

DATE OF RELEASE/EXPIRATION

This activity will be released on November 12, 2021 and is valid until November 12, 2022. Requests for credit must be made no later than November 12, 2022.

TARGET AUDIENCE

The educational design of this activity addresses the needs neurologists, pediatric neurologists, epileptologists, pediatric epileptologists, pediatricians, primary care providers, general practitioners, nurses, nurse practitioners, physician assistants, and pharmacists involved and/or interested in the management of patients with DS.

STATEMENT OF NEED/PROGRAM OVERVIEW

Despite the importance of early diagnosis, Dravet syndrome (DS) is often misdiagnosed in children and is thought to be underdiagnosed in adults with epilepsy. Making a correct and early diagnosis is critical to avoiding unnecessary testing, choosing the best treatment available, and staying away from medications that can exacerbate the condition.

In addition, until recently, very little clinical evidence was available to guide the treatment of DS. Published several years ago, the guidelines do not consider the latest randomized clinical‐trial data on efficacy and safety of newer therapeutic options.

Join our esteemed panel, Dr. Danielle Andrade and Dr. Mary Zupanc, for a case-based discussion of the accurate and timely diagnosis of DS in children and adults. Once a diagnosis has been established, these experts will explore optimal treatment selections and strategies for shared decision-making with patients, families, and caregivers. Panelists will also review the importance of multidisciplinary collaborations between specialists to ensure seizures, non-seizure symptoms, side-effects, and comorbidities are addressed.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:
  • •Review data from clinical trials of new antiseizure medications as related to the standard of care of DS management
  • •Evaluate each patient’s response to antiseizure medications for prompt adjustment of therapy
  • •Confirm a diagnosis of DS in children presenting with symptoms or in children and adults presenting with DRE using new diagnostic approaches that include diagnostic testing
  • •Devise a multidisciplinary approach to DS management to address seizure- and non‐seizure‐related symptoms

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACIST ACCREDITATION STATEMENT

ACPE LogoGlobal Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

CREDIT DESIGNATION

Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-21-305-H01-P)
This is a knowledge-based activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test. For pharmacist/ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship
Danielle Andrade, MD, MSc, FRCPC, CSCN (EEG)
Professor of Medicine (Neurology),
Medical Director, Epilepsy Program
Director of Epilepsy Genetics Research Program
Director, Epilepsy Transition Program
University of Toronto
Consulting Fee: Stoke Therapeutic
Honoraria: Biocodex
Speakers’ Bureau: Eisai
Investigator Initiated Grant: Biocodex, Zogenix
Mary Lynn Zupanc, MD, FAAP, FAAN
Professor, Department of Pediatrics and Neurology
University of California-Irvine
CHOC-Children's hospital
Contracted Research: Zogenix
Speakers’ Bureau: Zogenix

The planners and managers have the following relevant financial relationships with ineligible companies:
Name of Planner or Manager Reported Financial Relationship
Rhys Williams, RN, MSN, FNP Nothing to disclose
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Kim Rodriguez Nothing to disclose
Eve Wilson Nothing to disclose
Alissa Yost Nothing to disclose
 

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact NeuroSeriesLive.com at 1-877-394-1306 or at Support@NeuroSeriesLive.com.
Global Logo PQH Logo
Dravet Syndrome: Transition from Pediatric to Adult Care
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the Dravet Syndrome Foundation and the National Organization for Rare Disorders, Inc.

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Zogenix, Inc.

DATE OF RELEASE/EXPIRATION

This activity will be released on October 28, 2021 and is valid until October 28, 2022. Requests for credit must be made no later than October 28, 2022.

TARGET AUDIENCE

The educational design of this activity addresses the needs neurologists, pediatric neurologists, epileptologists, pediatric epileptologists, pediatricians, primary care providers, general practitioners, nurses, nurse practitioners, physician assistants, and pharmacists involved and/or interested in the management of patients with DS.

STATEMENT OF NEED/PROGRAM OVERVIEW

The transition of care from a pediatric to an adult setting is an increasingly critical time in the management of Dravet syndrome (DS). Unfortunately, many who have been through the transition process express dissatisfaction with the quality of the experience and with outreach from providers. Clinicians need to be comfortable formulating an individualized transition plan for their patients and communicating with patients, caregivers, and families to ensure that the plan is understood and agreed upon.

Join an expert panel of clinicians and caregivers for an exploration of the transition from adolescent to adult care in DS. Faculty will review the timing of the transition process, the identification of appropriate clinicians to receive transitioning patients, and communication strategies to ensure patients and caregivers understand and are involved in the transition process. The importance of dedicated roles, such as a Transition Navigator, on the care team will also be discussed.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:
  • Describe the consequences of a delayed diagnosis of DS such as in adults with DRE
  • Describe the unique seizure and non‐seizure related needs of adult patients with DS
  • Devise strategies to address challenges related to transitioning from pediatric to adult multidisciplinary care
  • Identify tools and support groups to assist caregivers in providing care for an individual with DS and transitioning from pediatric to adult care

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACIST ACCREDITATION STATEMENT

ACPE Logo

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

CREDIT DESIGNATION

Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-21-170-H01-P)

This is a knowledge-based activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test. For pharmacist/ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship
M. Scott Perry, MD
Head of Neurosciences
Cook Children’s Medical Center
Consulting Fee: Biomarin, Encoded, Greenwich biosciences, Neurelis, Stoke, Taysha, Zogenix
Contracted Research: Encoded, Greenwich Biosciences, Marinus, Ovid, Stoke, Zogenix
Speakers’ Bureau: Greenwich Biosciences, Zogenix
Danielle M. Andrade, MD, MSc, FRCPC, CSCN (EEG)
Professor of Medicine (Neurology)
Medical Director, Epilepsy Program
Director of Epilepsy Genetics Research Program
Director, Epilepsy Transition Program
University of Toronto
Consulting Fee: Stoke Therapeutic
Honoraria: Biocodex
Speakers’ Bureau: Eisai
Investigator Initiated Grant: Biocodex, Zogenix
Veronica Hood, PhD
Scientific Director
Dravet Syndrome Foundation
Nothing to disclose
Sharon Canino
Parent of an adult with Dravet syndrome
Nothing to disclose

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager Reported Financial Relationship
Rhys Williams, RN, MSN, FNP Nothing to disclose
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Kim Rodriguez Nothing to disclose
Carole Drexel Nothing to disclose
Eve Wilson Nothing to disclose
Alissa Yost Nothing to disclose

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact NeuroSeriesLive.com at 1-877-394-1306 or at Info@NeuroSeriesLive.com or Support@NeuroSeriesLive.com.
Global Logo PQH Logo
Managing Dravet Syndrome: Aiming for Better Outcomes
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the Dravet Syndrome Foundation and the National Organization for Rare Disorders, Inc.

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Zogenix, Inc.

DATE OF RELEASE/EXPIRATION

This activity will be released on September 23, 2021 and is valid until June 23, 2022. Requests for credit must be made no later than June 23, 2022.

TARGET AUDIENCE

The educational design of this activity addresses the needs neurologists, pediatric neurologists, epileptologists, pediatric epileptologists, pediatricians, primary care providers, general practitioners, nurses, nurse practitioners, physician assistants, and pharmacists involved and/or interested in the management of patients with DS.

STATEMENT OF NEED/PROGRAM OVERVIEW

For years, a 50% or greater reduction in seizure frequency has been a dominant endpoint to assess the efficacy of antiepileptic drugs in the treatment of Dravet syndrome (DS). However the impact of this endpoint on outcomes that are clinically meaningful to the patient has been debated. In practice, clinicians must balance reduction of seizure burden with adverse effects of therapies, as this endpoint is rarely achieved. While seizure control is extremely important, patient visits are often spent discussing the non‐seizure consequences of epilepsy syndromes, such as cognitive, psychological, and social issues. If seizures significantly improve, but comorbidities worsen, patients and their families often view this as a net negative outcome.

Join moderator Joseph Sullivan, MD and speaker M. Scott Perry, MD for an in-depth discussion of the need for validated, reliable, and usable instruments to measure non‐seizure outcomes in patients with DS, in both clinical trials and the clinic. These expert panelists will review the benefits and limitations of traditional DS medications, the roles of newer agents for DS, and evolving standards for evaluating treatment success. Framed by patient case vignettes, clinicians will leave this activity with a better understanding of the rationale for measuring success “beyond seizure numbers,” along with practical strategies to incorporate caregiver and patient input into care decisions.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:
  • Summarize the limitations of traditional antiseizure medications in reducing frequency of seizures due to DS
  • Examine seizure and non-seizure measures of treatment success for DS
  • Devise strategies to measure DS treatment success incorporating assessments from patients, caregivers, and HCPs

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACIST ACCREDITATION STATEMENT

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

ACPE Logo

CREDIT DESIGNATION

Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-21-152-H01-P)

This is a knowledge-based activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 100% on the post-test. For pharmacist/ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship
M. Scott Perry, MD
Head of Neurosciences
Cook Children’s Medical Center
Consulting Fee: Biomarin, Encoded, Greenwich biosciences, Neurelis, Stoke, Taysha, Zogenix
Contracted Research: Encoded, Greenwich Biosciences, Marinus, Ovid, Stoke, Zogenix
Speakers’ Bureau: Greenwich Biosciences, Zogenix
Joseph Sullivan, MD
Professor of Neurology & Pediatrics
University of California San Francisco
Consulting Fee: Encoded Therapeutics, Epilepsy Study Consortium, Epygenix Therapeutics, Greenwich Biosciences, Invitae, Knopp Biosciences, Longboard Pharma, Xenon
Contracted Research: Biopharm, Encoded Therapeutics, Marinus Pharmaceuticals, Stoke Therapeutics, Zogenix
Stock Shareholder: Epygenix Therapeutics

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager Reported Financial Relationship
Rhys Williams, RN, MSN, FNP Nothing to disclose
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Kim Rodriguez Nothing to disclose
Alissa Yost Nothing to disclose
Carole Drexel Nothing to disclose
Wendy Fry – Caregiver Nothing to disclose
Barbara Swoyer – Caregiver Nothing to disclose

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact NeuroSeriesLive.com at 1-877-394-1306 or at Info@NeuroSeriesLive.com or Support@NeuroSeriesLive.com.
   
Global Logo PQH Logo

Dravet Syndrome: Best Practices for Seizure‐ and Non‐Seizure‐related Symptoms

This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the Dravet Syndrome Foundation and the National Organization for Rare Disorders, Inc.

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Zogenix, Inc.

DATE OF RELEASE/EXPIRATION

This activity was released on June 23, 2021 and is valid for 12 months. Requests for credit must be made no later than June 23, 2022.

TARGET AUDIENCE

The educational design of this activity addresses the needs of neurologists, pediatric neurologists, epileptologists, pediatric epileptologists, pediatricians, primary care providers, general practitioners, nurses, nurse practitioners, physician assistants, and pharmacists involved and/or interested in the management of patients with DS.

STATEMENT OF NEED/PROGRAM OVERVIEW

Dravet syndrome (DS) is among the most challenging epilepsy syndromes due to intractable seizures, recurrent status epilepticus, comorbidities such as intellectual disability, and an increased mortality rate. Prolonged or repetitive seizures diminish quality of life not only for patients, but also for parents and caregivers. Improved awareness of DS may lead to earlier diagnoses, improved seizure control and ability to reach clinically meaningful outcomes. In addition, a correct and early diagnosis can ensure that clinicians do not perform unnecessary testing, choose the best treatment available, and avoid medications that can exacerbate the condition. Join esteemed experts Kelly Knupp, MD, MSCS and Elaine Wirrell, MD, FRCPC as they discuss the benefits of early management of DS, the place of newest options such as fenfluramine in the treatment algorithm along with practical strategies for a multidisciplinary approach to DS.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:
  • Explain how to incorporate data from clinical trials of new antiseizure medications into the standard of care for DS management
  • Critically appraise the place of newly available agents to reduce seizures and enhance overall patient outcomes in the management algorithm of DS
  • Summarize the multidisciplinary approach to patients with DS

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACIST ACCREDITATION STATEMENT

ACPE Logo Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

CREDIT DESIGANTION

Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-21-095-H01-P) This is a knowledge-based activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test. For pharmacist/ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated. The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship
Kelly G. Knupp, MD, MSCS Associate Professor of Pediatrics and Neurology Co-Director, Neurology Research University of Colorado Children’s Hospital Colorado Consulting Fee: Biocodex, Encoded, Epygenix, Stoke, Zogenix Contracted Research: Encoded, Stoke, Zogenix
Elaine C. Wirrell, MD, FRCPC Professor of Child and Adolescent Neurology Consultant and Director of Pediatric Epilepsy Mayo Clinic, Rochester, MN Consulting Fee (e.g., Advisory Board): Encoded, Zogenix (all monies to Mayo Clinic), GW Pharma (all monies to Mayo Clinic) Contracted Research: Site Investigator - Zogenix (all monies to Mayo Clinic), Stoke
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner or Manager Reported Financial Relationship
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Ashley Marostica, RN, MSN Nothing to disclose
Alissa Yost Nothing to disclose
Carole Drexel Nothing to disclose
 

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com. Technical Support: For any technical issues or issues with your CME Certificate, please contact NeuroSeriesLive.com at 1-877-394-1306 or at Info@NeuroSeriesLive.com or Support@NeuroSeriesLive.com.